206 related articles for article (PubMed ID: 35881486)
1. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses.
Romain G; Strati P; Rezvan A; Fathi M; Bandey IN; Adolacion JRT; Heeke D; Liadi I; Marques-Piubelli ML; Solis LM; Mahendra A; Vega F; Cooper LJ; Singh H; Mattie M; Bot A; Neelapu SS; Varadarajan N
J Clin Invest; 2022 Sep; 132(17):. PubMed ID: 35881486
[TBL] [Abstract][Full Text] [Related]
2. CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma.
Ghosh A; Marques-Piubelli ML; Wang X; Sheu TG; Cheng J; Khan K; Lu W; Manning J; Tang G; Solis LM; Vega F
Virchows Arch; 2022 Oct; 481(4):659-663. PubMed ID: 35622145
[TBL] [Abstract][Full Text] [Related]
3. A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals.
Demetriou P; Abu-Shah E; Valvo S; McCuaig S; Mayya V; Kvalvaag A; Starkey T; Korobchevskaya K; Lee LYW; Friedrich M; Mann E; Kutuzov MA; Morotti M; Wietek N; Rada H; Yusuf S; Afrose J; Siokis A; ; Meyer-Hermann M; Ahmed AA; Depoil D; Dustin ML
Nat Immunol; 2020 Oct; 21(10):1232-1243. PubMed ID: 32929275
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
6. Adhesive bond dynamics in contacts between T lymphocytes and glass-supported planar bilayers reconstituted with the immunoglobulin-related adhesion molecule CD58.
Dustin ML
J Biol Chem; 1997 Jun; 272(25):15782-8. PubMed ID: 9188475
[TBL] [Abstract][Full Text] [Related]
7. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
8. Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model.
Shao T; Shi W; Zheng JY; Xu XX; Lin AF; Xiang LX; Shao JZ
Front Immunol; 2018; 9():1204. PubMed ID: 29904386
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
10. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
11. Endothelial cell costimulation of T cell activation through CD58-CD2 interactions involves lipid raft aggregation.
Mestas J; Hughes CC
J Immunol; 2001 Oct; 167(8):4378-85. PubMed ID: 11591762
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
Salaroli A; Spilleboudt C; Bron D; Lewalle P
Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the CD2-binding domain of CD58 (lymphocyte function-associated antigen 3) at 1.8-A resolution.
Ikemizu S; Sparks LM; van der Merwe PA; Harlos K; Stuart DI; Jones EY; Davis SJ
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4289-94. PubMed ID: 10200255
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
[TBL] [Abstract][Full Text] [Related]
17. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
18. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
20. The CD2-CD58 axis: A novel marker predicting poor prognosis in patients with low-grade gliomas and potential therapeutic approaches.
Wu M; Chen Y; Hua G; Chunhui L
Immun Inflamm Dis; 2023 Oct; 11(10):e1022. PubMed ID: 37904707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
